Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000962647> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W2000962647 endingPage "130" @default.
- W2000962647 startingPage "127" @default.
- W2000962647 abstract "Abstract Aim: To report the efficacy and safety of infliximab in the treatment of active rheumatoid arthritis (RA) in Chinese patients. Methods: This is a multicentre double‐blind placebo controlled study. Patients with active RA despite being on a stable dose of methotrexate were randomly assigned to receive either infliximab 3 mg/kg body weight or placebo infusion at weeks 0, 2, 6 and 14. All patients continued their stable dose of methotrexate throughout the study. Patients were assessed at weeks 0, 2, 6, 14 and 18 for the American College of Rheumatology (ACR) 20%, 50% and 70% response (ACR20, 50 and 70, respectively). Health assessment questionnaire (HAQ), erythrocyte sedimentation rate (ESR), c‐reactive protein (CRP), duration of morning stiffness and adverse effects were monitored. Results: Infliximab was effective in improving the disease activity of RA with significant ACR20 response observed at week 2 (infliximab vs . placebo 52.87% vs . 13.95%, P < 0.05). Significant differences in the ACR20 and ACR50 response rates between the two treatment groups were also observed at week 18 (75.86% and 43.68% of patients receiving infliximab vs . 48.84% and 25.58% and 13.95% of patients on placebo, P = 0.0003 and P = 0.011, respectively). Infliximab was generally well tolerated. The rate of adverse events and withdrawal due to adverse events were similar between the two groups. Most adverse reactions were transient. One patient in the infliximab group developed tuberculosis during the study. One patient in the placebo group developed antinuclear antibodies without obvious signs of systemic lupus erythematosus. Conclusion: In this preliminary study, infliximab infusions, at a dose of 3 mg/kg body weight given at various intervals over 14 weeks, were effective in controlling the signs and symptoms of active RA in Chinese. Infliximab also appeared to be well tolerated. Further studies involving a larger number of patients over a more prolonged period will further evaluate the long‐term efficacy and safety of infliximab in this group of patients." @default.
- W2000962647 created "2016-06-24" @default.
- W2000962647 creator A5001062703 @default.
- W2000962647 creator A5012912140 @default.
- W2000962647 creator A5025869715 @default.
- W2000962647 creator A5031993303 @default.
- W2000962647 creator A5034417510 @default.
- W2000962647 creator A5073919466 @default.
- W2000962647 creator A5090435133 @default.
- W2000962647 date "2006-07-12" @default.
- W2000962647 modified "2023-10-13" @default.
- W2000962647 title "Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a preliminary study from China" @default.
- W2000962647 cites W1985763670 @default.
- W2000962647 cites W2038535814 @default.
- W2000962647 cites W2319957449 @default.
- W2000962647 doi "https://doi.org/10.1111/j.1479-8077.2006.00186.x" @default.
- W2000962647 hasPublicationYear "2006" @default.
- W2000962647 type Work @default.
- W2000962647 sameAs 2000962647 @default.
- W2000962647 citedByCount "44" @default.
- W2000962647 countsByYear W20009626472012 @default.
- W2000962647 countsByYear W20009626472013 @default.
- W2000962647 countsByYear W20009626472014 @default.
- W2000962647 countsByYear W20009626472015 @default.
- W2000962647 countsByYear W20009626472016 @default.
- W2000962647 countsByYear W20009626472017 @default.
- W2000962647 countsByYear W20009626472018 @default.
- W2000962647 countsByYear W20009626472020 @default.
- W2000962647 countsByYear W20009626472022 @default.
- W2000962647 countsByYear W20009626472023 @default.
- W2000962647 crossrefType "journal-article" @default.
- W2000962647 hasAuthorship W2000962647A5001062703 @default.
- W2000962647 hasAuthorship W2000962647A5012912140 @default.
- W2000962647 hasAuthorship W2000962647A5025869715 @default.
- W2000962647 hasAuthorship W2000962647A5031993303 @default.
- W2000962647 hasAuthorship W2000962647A5034417510 @default.
- W2000962647 hasAuthorship W2000962647A5073919466 @default.
- W2000962647 hasAuthorship W2000962647A5090435133 @default.
- W2000962647 hasBestOaLocation W20009626471 @default.
- W2000962647 hasConcept C126322002 @default.
- W2000962647 hasConcept C141071460 @default.
- W2000962647 hasConcept C142724271 @default.
- W2000962647 hasConcept C17991360 @default.
- W2000962647 hasConcept C197934379 @default.
- W2000962647 hasConcept C198451711 @default.
- W2000962647 hasConcept C204787440 @default.
- W2000962647 hasConcept C27081682 @default.
- W2000962647 hasConcept C2777077863 @default.
- W2000962647 hasConcept C2777138892 @default.
- W2000962647 hasConcept C2777575956 @default.
- W2000962647 hasConcept C2778143017 @default.
- W2000962647 hasConcept C2779384505 @default.
- W2000962647 hasConcept C2781059491 @default.
- W2000962647 hasConcept C71924100 @default.
- W2000962647 hasConcept C90924648 @default.
- W2000962647 hasConceptScore W2000962647C126322002 @default.
- W2000962647 hasConceptScore W2000962647C141071460 @default.
- W2000962647 hasConceptScore W2000962647C142724271 @default.
- W2000962647 hasConceptScore W2000962647C17991360 @default.
- W2000962647 hasConceptScore W2000962647C197934379 @default.
- W2000962647 hasConceptScore W2000962647C198451711 @default.
- W2000962647 hasConceptScore W2000962647C204787440 @default.
- W2000962647 hasConceptScore W2000962647C27081682 @default.
- W2000962647 hasConceptScore W2000962647C2777077863 @default.
- W2000962647 hasConceptScore W2000962647C2777138892 @default.
- W2000962647 hasConceptScore W2000962647C2777575956 @default.
- W2000962647 hasConceptScore W2000962647C2778143017 @default.
- W2000962647 hasConceptScore W2000962647C2779384505 @default.
- W2000962647 hasConceptScore W2000962647C2781059491 @default.
- W2000962647 hasConceptScore W2000962647C71924100 @default.
- W2000962647 hasConceptScore W2000962647C90924648 @default.
- W2000962647 hasIssue "2" @default.
- W2000962647 hasLocation W20009626471 @default.
- W2000962647 hasOpenAccess W2000962647 @default.
- W2000962647 hasPrimaryLocation W20009626471 @default.
- W2000962647 hasRelatedWork W1569392312 @default.
- W2000962647 hasRelatedWork W1897160555 @default.
- W2000962647 hasRelatedWork W2000293965 @default.
- W2000962647 hasRelatedWork W2067177021 @default.
- W2000962647 hasRelatedWork W2072640801 @default.
- W2000962647 hasRelatedWork W2090686119 @default.
- W2000962647 hasRelatedWork W2093504865 @default.
- W2000962647 hasRelatedWork W2133832905 @default.
- W2000962647 hasRelatedWork W2409753288 @default.
- W2000962647 hasRelatedWork W4251398023 @default.
- W2000962647 hasVolume "9" @default.
- W2000962647 isParatext "false" @default.
- W2000962647 isRetracted "false" @default.
- W2000962647 magId "2000962647" @default.
- W2000962647 workType "article" @default.